Central Serous Chorioretinopathy Clinical Trial
Official title:
Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Rare Retinal and Choroidal Diseases
NCT number | NCT02141308 |
Other study ID # | IRB00010511 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 2014 |
Est. completion date | December 2026 |
This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels. The purpose of measuring blood flow in the retina and choroid is to 1.) determine if rare diseases in these structures causes a change in blood flow compared to healthy eyes and 2.) find out if areas of changed blood flow line up with areas of damage that appear on conventional testing.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | December 2026 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 7 Years to 100 Years |
Eligibility | Subject-Level Criteria: Inclusion a. Diagnosis of retinal or choroidal disease Exclusion 1. Inability to give informed consent. 2. Inability to complete study tests within a 30 day period 3. Significant renal disease, defined as a history of chornic renal failure requiring dialysis or kidney transplant. 4. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease, and glycemic control). 5. Blood pressure > 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible. 6. Women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months due to unknown safety of fluorescein angiography. Study-Eye Criteria: Inclusion a. Diagnosis of retinal or choroidal disease Exclusion 1. Inability to maintain stable fixation for OCT imaging. 2. An ocular condition is present that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (i.e. cataract) 3. Substantial cataract that, in the opinion of the investigator, is likely to decrease visual acuity by 3 lines or more (i.e. cataract would be reducing acuity to 20/40 or worse if the eye was otherwise normal). 4. Media opacity or otherwise that would prevent either fixation or ability to obtain adequate images as determined by the examiner. |
Country | Name | City | State |
---|---|---|---|
United States | Casey Eye Institute, Oregon Health & Science University | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Oregon Health and Science University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Retinal and Choroidal Blood Flow | Determination whether disease affecting the retina and/or choroid shows a change in blood flow that differs from healthy eyes. Total retinal/choroidal blood flow will be measured in uL/min. | One year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03497000 -
Effects of OCTA-guided PDT in Acute CSC
|
N/A | |
Recruiting |
NCT03692169 -
The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC
|
||
Not yet recruiting |
NCT02215330 -
A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy
|
Phase 2/Phase 3 | |
Completed |
NCT01971190 -
Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy
|
Phase 2 | |
Completed |
NCT01990677 -
Eplerenone for the Treatment of Central Serous Chorioretinopathy
|
N/A | |
Active, not recruiting |
NCT01710332 -
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
|
Phase 2 | |
Active, not recruiting |
NCT00403884 -
Selective RPE Laser Treatment (SRT) for Various Macular Diseases
|
N/A | |
Recruiting |
NCT05570591 -
Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy
|
N/A | |
Recruiting |
NCT05589974 -
Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
|
||
Completed |
NCT05104138 -
Eplerenone Versus PDT: Comparative Study by OCTA
|
||
Terminated |
NCT01982383 -
Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy
|
N/A | |
Completed |
NCT01880788 -
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
|
N/A | |
Completed |
NCT01019668 -
Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy
|
N/A | |
Completed |
NCT01327170 -
Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy
|
N/A | |
Recruiting |
NCT06346405 -
Central Serous Chorioretinopathy and Micropulse Laser Treatment
|
||
Completed |
NCT01822561 -
Eplerenone for Central Serous Chorioretinopathy
|
Phase 2 | |
Completed |
NCT00802906 -
Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)
|
N/A | |
Withdrawn |
NCT05679180 -
Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE
|
N/A | |
Completed |
NCT05686421 -
Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations
|
N/A | |
Completed |
NCT03758963 -
Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy
|
N/A |